HK Stock Market Move | CUTIA-B (02487) rose by over 18% during trading, and is expected to introduce three blockbuster pipeline updates this year. Institutions are optimistic about the future growth space of the medical beauty sector.

CUTIA-B (02487) rose more than 18% in mid-trading, up 14.65% as of the time of publication, at 7.28 Hong Kong dollars, with a turnover of 30.9444 million Hong Kong dollars. On the news front, Founder's previous research report pointed out that the company is a new force in the rapidly growing market for general skin disease treatment and care, focusing on commercialization and driving innovation. The commercialization of the Minoxidil series products and the functional skincare brand OMA has made a breakthrough, currently rapidly transitioning to a multi-matrix iteration. In the next 25 years, it will be an important node for the landing of the heavy pipeline of topical minocycline, topical finasteride, and hemp ointment. The company's short-term commercial drive is strong and high-growth, combined with a leading role in long-term research and development barriers. It is expected that the revenue will be approximately 6-10 billion yuan in 2025-2026, with the current valuation at a low level and the additional new pipeline incremental focus on the flexible opportunities of pipeline approvals. Caitong Securities believes that in the long term, with the improvement of industry penetration rate, the increase in the rate of light medical beauty, and the increase in the rate of domestic substitution, it continues to be optimistic about the future growth space of the medical beauty sector. Kaiyuan Securities stated that in the long term, the logic of the continuous improvement in medical beauty "penetration rate + localization rate + compliance level" remains unchanged. The medical beauty upstream manufacturers that take the lead in laying out differentiated pipelines are expected to seize the high ground of consumer mindshare. It is recommended to focus on recombinant collagen, regenerative, and hair tracks. In addition, downstream medical beauty institutions are also expected to achieve a simultaneous increase in market share and profitability in the context of long-tail clearance and a rich upstream product background. Key recommendations include Science & Technology, among others.